Rich Pharmaceuticals Inc. (fka RCHA)

[stervc]

RCHA FDA Approval News & Must See Videos…

RCHA is a fully reporting company that files audited financials with the SEC that has received FDA Approval to start Phase I/II (1/2) for treating Acute Myelocytic Leukemia (AML) and Hodgkin's Lymphoma (HL) with its principal doctor, Dr. Tontanai Numbenjapon, who will commence Clinical Trials in Phramongkutklao Hospital in Thailand per the recent news indicated below:

http://www.richpharmaceuticals.com/


http://www.marketwired.com/press-release/rich-pharmaceuticals-announces-principal-doctor-for-clinical-trials-otc-pink-rcha-2222967.htm
Now that Rich Pharmaceuticals has filed an IND (https://youtu.be/0CCtXc43a0I) with the FDA and received approval to start phase I/II (https://youtu.be/1WvlzbzKGqE), operations have progressed to the site level at Phramongkutklao Hospital and a full package has been submitted to the hospitals IRB (Review Board). "Rich Pharmaceuticals is pleased to have reached such a milestone and we look forward to patient enrollment at Phramongkutklao Hospital with the help of Dr. Numbenjapon," stated Mr. Chang.
...
Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. RP-323 is a phorbol ester, which induces differentiation and/or apoptosis in multiple cell lines and primary cells, activates protein kinase C (PKC), and modulates the activity of multiple downstream cell signaling pathways, including mitogen-activated protein kinase (MAPK) pathways. RP-323 induces PKC to produce NF kappa, which then produces NF kappa B that has the ability to regulate cellular responses by entering into the nucleus of cells. NF kappa B binds to DNA and changes the nature of the cell and (1) induces differentiation; (2) induces proliferation; (3) cytokine induction; (4) and/or apoptosis. Find out more at www.richpharmaceuticals.com


http://www.marketwired.com/press-release/rich-pharmaceuticals-announces-principal-doctor-for-clinical-trials-otc-pink-rcha-2222967.htm
June 21, 2017 06:02 ET

Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials

BEVERLY HILLS, CA--(Marketwired - Jun 21, 2017) - Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology announced today its principal doctor, Dr. Tontanai Numbenjapon, will commence clinical trials in Phramongkutklao Hospital in Thailand.

Dr. Numbenjapon specializes in medical oncology, hematology, and stem cell transplantation. He has over 14 years of experience in Hematology and Oncology.

"We are confident that Dr. Numbenjapon is the best and most qualified physician to head our research abroad, and look forward to his guidance as we embark on the next phase of our clinical studies," said Ben Chang, CEO.

RCHA FDA Approval/Must See Videos

What is an IND - Dr. Mac Moretz of Rich Pharmaceuticals
https://www.youtube.com/watch?v=0CCtXc43a0I&feature=youtu.be

Dr. Mac of Rich Pharmaceuticals talks about the FDA Review Process
https://www.youtube.com/watch?v=1WvlzbzKGqE&feature=youtu.be

v/r
Sterling